These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10991829)

  • 1. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.
    Poole K
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2595-9. PubMed ID: 10991829
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efflux pumps of gram-positive bacteria and resistance to fluoroquionolones].
    Egorov AM; Sazykin IuO
    Antibiot Khimioter; 2001; 46(8):3-5. PubMed ID: 11871317
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
    Prats G; Roig C; Miró E; Navarro F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impermeability to quinolones in gram-positive and gram-negative bacteria.
    Bryan LE; Bedard J
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):232-9. PubMed ID: 1864283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.
    Poole K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2233-41. PubMed ID: 10952561
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
    Piddock LJ; Panchal S; Norte V
    J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria.
    Lambert PA
    J Appl Microbiol; 2002; 92 Suppl():46S-54S. PubMed ID: 12000612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to quinolones in mycobacteria.
    Cambau E; Jarlier V
    Res Microbiol; 1996; 147(1-2):52-9. PubMed ID: 8761723
    [No Abstract]   [Full Text] [Related]  

  • 10. Preliminary study of the in vitro activity of irloxacin against mycobacteria.
    Casal M; Gutierrez J; Ruiz P; Moreno G
    Chemotherapy; 1995; 41(3):204-7. PubMed ID: 7656667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
    Hoban D; Grabowski M; Koss J; Weselowski V
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis.
    Banerjee SK; Bhatt K; Rana S; Misra P; Chakraborti PK
    Biochem Biophys Res Commun; 1996 Sep; 226(2):362-8. PubMed ID: 8806641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects.
    Gootz TD; Brighty KE
    Med Res Rev; 1996 Sep; 16(5):433-86. PubMed ID: 8865150
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
    Renau TE; Sanchez JP; Shapiro MA; Dever JA; Gracheck SJ; Domagala JM
    J Med Chem; 1995 Jul; 38(15):2974-7. PubMed ID: 7636859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens.
    Debbia EA; Pesce A; Schito GC
    Am J Med; 1992 Apr; 92(4A):45S-47S. PubMed ID: 1316070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activity of the new quinolone Bay y3118 against clinical isolates.
    Ravizzola G; Pizzi R; Pirali F; Turano A
    J Chemother; 1994 Dec; 6(6):392-8. PubMed ID: 7699426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M; Coll R; Esteve M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro activity of fluoroquinolones against gram-positive bacteria.
    Eliopoulos GM
    Drugs; 1995; 49 Suppl 2():48-57. PubMed ID: 8549407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.
    Piddock LJ; Marshall AJ; Jin YF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):422-7. PubMed ID: 8203834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.